New drug combo aims to tackle Hard-to-Treat lymphoma
NCT ID NCT07691606
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests a new drug called ARC-02, given together with rituximab, in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least two prior treatments. The main goals are to check the safety of ARC-02 and find the best dose, while also looking at whether it can shrink tumors. The trial is early-stage, so it focuses on side effects and how the drug moves through the body, not yet on a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARC-02 (given by IV infusion) plus rituximab
- What this could lead to
- If successful, this could provide a new treatment option for people with B-cell non-Hodgkin lymphoma who have not responded to other therapies.
- What could go wrong
- This is an early-phase trial focused on safety and dosing, so it is not yet known whether ARC-02 will effectively shrink tumors or improve outcomes. Side effects are possible and will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST Papa Giovanni XXIII
NOT_YET_RECRUITINGBergamo, 24127, Italy
-
Austin Health
NOT_YET_RECRUITINGMelbourne, 3084, Australia
-
CHU Nantes - Hotel Dieu
NOT_YET_RECRUITINGNantes, 44000, France
-
Centre Hospitalier Universitaire de Lille (CHU Lille) - Hopital Claude Huriez
NOT_YET_RECRUITINGLille, 59037, France
-
Centro di Riferimento Oncologico (CRO Aviano)
NOT_YET_RECRUITINGAviano, 33081, Italy
-
Froedtert & Medical College of Wisconsin
NOT_YET_RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Gold Coast Hospital
NOT_YET_RECRUITINGSouthport, 4215, Australia
-
Hopital Henri-Mondor
NOT_YET_RECRUITINGCréteil, 94010, France
-
Hospital General San Pedro De Alcantara
NOT_YET_RECRUITINGCáceres, 10003, Spain
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 8035, Spain
-
Hospital Universitario Virgen del Rocio
NOT_YET_RECRUITINGSeville, 41013, Spain
-
Hôpital Lyon Sud
NOT_YET_RECRUITINGLyon, 69495, France
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94805, France
-
Istituto Clinico Humanitas
NOT_YET_RECRUITINGRozzano, 20089, Italy
-
Levine Cancer Institute
NOT_YET_RECRUITINGCharlotte, North Carolina, 28204, United States
-
Linear Clinical Research
NOT_YET_RECRUITINGNedlands, 6009, Australia
-
Massey Cancer Center
NOT_YET_RECRUITINGRichmond, Virginia, 23298, United States
-
Monash Health
NOT_YET_RECRUITINGClayton, 3168, Australia
-
NYU Langone
NOT_YET_RECRUITINGNew York, New York, 10016, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
NOT_YET_RECRUITINGWarsaw, 02-781, Poland
-
Norton Cancer Institute
NOT_YET_RECRUITINGLouisville, Kentucky, 40202, United States
-
Pratia MCM Krakow
NOT_YET_RECRUITINGKrakow, 30-727, Poland
-
Pratia Onkologia Katowice
NOT_YET_RECRUITINGKatowice, 40-519, Poland
-
START Madrid - Hospital Universitario Madrid Sanchinarro
NOT_YET_RECRUITINGMadrid, 28050, Spain
-
Start Cala
RECRUITINGLos Angeles, California, 90025, United States
-
Summit Cancer Centers - North Spokane
RECRUITINGSpokane, Washington, 99208, United States
-
Szpital AidPort
NOT_YET_RECRUITINGSkorzewo, 60-185, Poland
-
The START Center for Cancer Care - Madrid (Fundacion Jimenez Diaz)
NOT_YET_RECRUITINGMadrid, 28040, Spain
-
University of Bologna
NOT_YET_RECRUITINGBologna, 40138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug boost standard therapy for a rare lymphoma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Smartwatches track hidden heart risk in blood cancer patients
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Drug combo aims to boost remission in rare lymphoma
- New transplant recipe aims to tame Graft-Versus-Host disease